pepsico glp 1 Why food makers aren't afraid of GLP-1 drugs How PepsiCo is adapting to

Preliminary data point toward beneficial effects of GIP agonism, as reported in findings from the SURPASS program that tirzepatide reduced UACR and slowed down eGFR declined in comparison with both placebo (53) and comparator drugs including insulin glargine (74, 75)

Abstract Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown notable advancements in managing blood sugar control

[48] They are highly transient, typically peaking during the initial 8-to-12-week dose-escalation phase before waning over time

Tesamorelin also preserves and may increase lean muscle tissue, making it valuable for body recomposition rather than just weight loss

2 Q3-U7)

Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB